Anti-infective drug discovery
3 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
GSK's R&D division contributing pharmaceutical industry data, compounds, and clinical trial infrastructure to large EU drug development and immunology consortia.
“Participates in COMBINE (MDR bacterial infections), AB-DiRecT (antibiotic tissue distribution), and ND4ID (diagnostics for infectious diseases).”
UK35 projects - FORSCHUNGSZENTRUM BORSTEL LEIBNIZ LUNGENZENTRUM
Leibniz lung disease research center specialized in tuberculosis drug development, clinical pharmacology, and anti-infective discovery across large European consortia.
“MepAnti project explores the methylerythritol phosphate pathway as a source of new anti-infective drug targets.”
DE7 projects - APTUIT (VERONA) SRL
Italian contract research organization providing preclinical pharmaceutical development, drug formulation, and industrial training for EU anti-infective and nanomedicine projects.
“INTEGRATE focused on Gram-negative antibacterial target validation; PRINT-AID developed personalized anti-infective medical devices.”
PrimaryIT3 projects